Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancer
J. Datta, X. Dai, A. Bianchi, I. De Castro Silva, S. Mehra, V. T. Garrido, P. Lamichhane, S. Singh, Z. Zhou, A. R. Dosch, F. Messagio, Y. Ban, O. Umland, P. J. Hosein, N. Nagathihalli, N. Merchant
This paper shows that combining MEK and STAT3 inhibitors reprograms stromal inflammation and enhances immunotherapy response in pancreatic cancer.
bioRxiv · Mar 7, 2021 · PreprintCancer Biology